1. Home
  2. IMMP vs MIN Comparison

IMMP vs MIN Comparison

Compare IMMP & MIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMMP
  • MIN
  • Stock Information
  • Founded
  • IMMP 1987
  • MIN 1988
  • Country
  • IMMP Australia
  • MIN United States
  • Employees
  • IMMP N/A
  • MIN N/A
  • Industry
  • IMMP Biotechnology: Pharmaceutical Preparations
  • MIN Trusts Except Educational Religious and Charitable
  • Sector
  • IMMP Health Care
  • MIN Finance
  • Exchange
  • IMMP Nasdaq
  • MIN Nasdaq
  • Market Cap
  • IMMP 211.1M
  • MIN 306.1M
  • IPO Year
  • IMMP N/A
  • MIN N/A
  • Fundamental
  • Price
  • IMMP $1.86
  • MIN $2.69
  • Analyst Decision
  • IMMP Buy
  • MIN
  • Analyst Count
  • IMMP 2
  • MIN 0
  • Target Price
  • IMMP $8.50
  • MIN N/A
  • AVG Volume (30 Days)
  • IMMP 648.0K
  • MIN 331.0K
  • Earning Date
  • IMMP 05-16-2025
  • MIN 01-01-0001
  • Dividend Yield
  • IMMP N/A
  • MIN 7.31%
  • EPS Growth
  • IMMP N/A
  • MIN N/A
  • EPS
  • IMMP N/A
  • MIN 0.08
  • Revenue
  • IMMP $3,019,249.00
  • MIN N/A
  • Revenue This Year
  • IMMP $11.25
  • MIN N/A
  • Revenue Next Year
  • IMMP $10.22
  • MIN N/A
  • P/E Ratio
  • IMMP N/A
  • MIN $33.38
  • Revenue Growth
  • IMMP 24.11
  • MIN N/A
  • 52 Week Low
  • IMMP $1.32
  • MIN $2.52
  • 52 Week High
  • IMMP $3.34
  • MIN $2.88
  • Technical
  • Relative Strength Index (RSI)
  • IMMP 53.43
  • MIN 52.32
  • Support Level
  • IMMP $1.44
  • MIN $2.65
  • Resistance Level
  • IMMP $2.71
  • MIN $2.71
  • Average True Range (ATR)
  • IMMP 0.17
  • MIN 0.03
  • MACD
  • IMMP 0.05
  • MIN 0.00
  • Stochastic Oscillator
  • IMMP 29.75
  • MIN 68.75

About IMMP Immutep Limited

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.

About MIN MFS Intermediate Income Trust

MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.

Share on Social Networks: